ArticleBMC endocrine disorders2025
Endocan levels in patients with hyperprolactinemia.
Article in BMC endocrine disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveElevated prolactin levels are considered a potential parameter associated with increased cardiovascular risk. The aim of our study is to investigate the possible role of Endocan levels in the cardiovascular risk associated with hyperprolactinemia by comparing patients with hyperprolactinemia to a healthy control group.
methodsThe study included 39 patients with hyperprolactinemia of various etiologies and 39 healthy controls. In both groups, cardiovascular risk-related parameters-including height, body weight, BMI, waist circumference, CRP, and lipid levels-were evaluated and recorded. Endocan levels were measured using the ELISA method.
resultsThe groups were comparable in age, sex, height, body weight, BMI, and waist circumference. No significant differences were found between the patient and control groups in terms of height, body weight, BMI, waist circumference, WBC count, fasting glucose, insulin levels, HOMA-IR, HbA1c, lipid profile, CRP, and 25(OH) vitamin D levels. However, serum Endocan levels were significantly higher in the hyperprolactinemic group (p = 0.028). In this group, Endocan levels showed a significant positive correlation with waist circumference, body weight, and BMI, and a negative correlation with WBC count.
conclusionOne of the key findings of our study is the elevated Endocan levels in patients with mildly increased prolactin levels (45.90 ± 2.72 ng/mL), indicating a higher cardiovascular risk. This may reflect the association between elevated prolactin and endothelial dysfunction. Further prospective studies with larger sample sizes and longer follow-up are needed to better evaluate Endocan levels in patients with hyperprolactinemia. CLINICAL TRIAL NUMBER: No applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.